← All trials
NCT05155332
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2022
- Primary completion
- Apr 17, 2025
- Completion date
- Jul 3, 2025
- First posted
- Dec 13, 2021
- Last posted
- Dec 16, 2021
- Enrollment
- 117
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.